The Hepatitis C Virus (HCV) results in an increased attraction of human neutrophils to its host cell by a basal and EGF-induced CXCR2 ligand expression

2015 ◽  
Vol 53 (12) ◽  
Author(s):  
C Gröpper ◽  
R Bartenschlager ◽  
D Häussinger ◽  
JG Bode
2014 ◽  
Vol 60 (1) ◽  
pp. S108-S109
Author(s):  
C. Gröpper ◽  
N. Triller ◽  
S. Eisenbürger ◽  
R. Bartenschlager ◽  
D. Häussinger ◽  
...  

2012 ◽  
Vol 85 (1) ◽  
pp. 71-82 ◽  
Author(s):  
Pasi Kaukinen ◽  
Maarit Sillanpää ◽  
Laura Nousiainen ◽  
Krister Melén ◽  
Ilkka Julkunen

Author(s):  
Alaa Elgohary ◽  
Abdo Elfiky

Hepatitis C Virus (HCV) is the main causative factor for liver cirrhosis and the development of liver cancer, with a confirmed ~ 180 million infections worldwide. E2 is an HCV structural protein responsible for virus entry to the host cell. Heat Shock Protein A5 (HSPA5), also termed BiP and GRP78, is the master regulator of the unfolded protein response mechanism, where it mainly localizes in the lumen of the Endoplasmic Reticulum (ER) in normal conditions. Under the stress of HCV infection or carcinogenesis, HSPA5 is upregulated. Consequently, HSPA5 escapes the ER retention localization and translocates to the cytoplasm and plasma membrane. Pep42, a cyclic peptide that was reported to target explicitly cell-surface HSPA5 in vivo. Owing to the high sequence and structural conservation between the C554-C566 region of HCV E2 and the Pep42, then we propose that the HCV E2 C554-C566 region could be the recognition site. The motivation of this work is to predict the possible binding mode between HCV E2 and HSPA5 by implementing molecular docking to test such proposed binding. Docking results reveal the high potent binding of the HCV E2 C554-C566 region to HSPA5 substrate-binding domain β (SBDβ). Moreover, the full-length HCV E2 also exhibits high binding potency to HSPA5 SBDβ. Defining the binding mode between HCV E2 and HSPA5 is of significance, so one can interfere with such binding and reducing the viral infection.


2005 ◽  
Vol 79 (21) ◽  
pp. 13778-13793 ◽  
Author(s):  
Marc P. Windisch ◽  
Michael Frese ◽  
Artur Kaul ◽  
Martin Trippler ◽  
Volker Lohmann ◽  
...  

ABSTRACT The Hepatitis C virus (HCV), a member of the family Flaviviridae, is a major cause of chronic liver disease. Patients are currently treated with alpha interferon (IFN-α) that is given alone or in combination with ribavirin. Unfortunately, this treatment is ineffective in eliminating the virus in a large proportion of individuals. IFN-induced antiviral activities have been intensively studied in the HCV replicon system. It was found that both IFN-α and IFN-γ inhibit HCV replicons, but the underlying mechanisms have not yet been identified. Of note is that nearly all of these studies were performed with the human hepatoma cell line Huh-7. Here, we report that genotypes 1b and 2a replicons also replicate in the human hepatoblastoma cell line HuH6. Similar to what has been described for Huh-7 cells, we observed that efficient HCV replication in HuH6 cells depends on the presence of cell culture-adaptive mutations and the permissiveness of the host cell. However, three major differences exist: in HuH6 cells, viral replication is (i) independent from ongoing cell proliferation, (ii) less sensitive to certain antiviral compounds, and (iii) highly resistant to IFN-γ. The latter is not due to a general defect in IFN signaling, as IFN-γ induces the nuclear translocation of signal transducer and activator of transcription 1 (STAT1), the enhanced transcription of several IFN-regulated genes, and the inhibition of unrelated viruses such as influenza A virus and Semliki Forest virus. Taken together, the results establish HuH6 replicon cells as a valuable tool for IFN studies and for the evaluation of antiviral compounds.


Sign in / Sign up

Export Citation Format

Share Document